Pluristem Therapeutics, Inc. has completed development of its second major cell product line and can now begin large-scale manufacturing for anticipated studies in a range of hematologic conditions. The cell product candidate, PLX-RAD, was created using Pluristem’s three dimensional cell expansion technology platform. The company’s first product, PLX-PAD, is currently in clinical trials for the treatment of peripheral artery disease, muscle injury and pulmonary arterial hypertension.   “We’ve ju...